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Abstract
Marfan syndrome is an autosomal dominantly inherited disorder of connective tissue with prominent skeletal, ocular, and
cardiovascular manifestations. Aortic aneurysm and dissection are the major determinants of premature death in untreated
patients. In previous work, we showed that extracts of aortic tissues from the mgR mouse model of Marfan syndrome
showed increased chemotactic stimulatory activity related to the elastin-binding protein. Aortic samples were collected
from 6 patients with Marfan syndrome and 8 with isolated aneurysms of the ascending aorta. Control samples were
obtained from 11 organ donors without known vascular or connective tissue diseases. Soluble proteins extracted from the
aortic samples of the two patient groups were compared against buffer controls and against the aortic samples from
controls with respect to the ability to induce macrophage chemotaxis as measured using a modified Boyden chamber, as
well as the reactivity to a monoclonal antibody BA4 against bioactive elastin peptides using ELISA. Samples from Marfan
patients displayed a statistically significant increase in chemotactic inductive activity compared to control samples.
Additionally, reactivity to BA4 was significantly increased. Similar statistically significant increases were identified for the
samples from patients with idiopathic thoracic aortic aneurysm. There was a significant correlation between the
chemotactic index and BA4 reactivity, and the increases in chemotactic activity of extracts from Marfan patients could be
inhibited by pretreatment with lactose, VGVAPG peptides, or BA4, which indicates the involvement of EBP in mediating the
effects. Our results demonstrate that aortic extracts of patients with Marfan syndrome can elicit macrophage chemotaxis,
similar to our previous study on aortic extracts of the mgR mouse model of Marfan syndrome (Guo et al., Circulation 2006;
114:1855-62).
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Introduction
Marfan syndrome (MFS) is an autosomal dominant inherited
disorder of connective tissue that is caused by mutations in the
gene for fibrillin-1 (FBN1), with prominent clinical manifestations
in the cardiovascular, skeletal and ocular systems. The high
mortality of untreated patients results almost exclusively from
cardiovascular complications such as acute aortic dissection or
rupture [1,2]. The pathogenesis of MFS is complex, and
numerous classes of abnormalities have been shown to result
from mutation in FBN1 [3]. Fibrillin-1 contributes to the
sequestration of TGFb in the extracellular matrix (ECM) and
thereby to the control of its bioavailability [4,5]. Mutation in
fibrillin-1 leads to increased TGFb signaling activity [6–9].
Additionally, a number of other aspects of the molecular
pathomechanism of MFS have been characterized in recent
years, including evidence that haploinsufficiency for fibrillin-1
contributes to failed microfibrillar assembly and the development
of disease [10,11], endothelial dysfunction and compromised
eNOS/Akt signaling [12–14], and alterations in the biosynthesis
of fibrillin-1 rich microfibrils [15,16].
Another line of research has examined the roles of proteases and
protein fragments in MFS. A number of groups have shown that
FBN1 gene mutations can increase the susceptibility of fibrillin to
proteolysis [17–23]. Missense mutations affecting either highly
conserved cysteine residues or residues of the calcium-binding
consensus sequence are common in MFS [24]. Presumably, such
mutations affect the structure and conformation of the cbEGF
module or cause alterations in interdomain flexibility [25,26] and
thereby expose the modules to proteases. There is histological
evidence of fragmentation [27,28] in addition to evidence of
alterations in matrix metalloproteinase (MMP) and tissue inhibitor
of MMP (TIMP) activity [29–31] in the aortic tissues of Marfan
patients. Another indication of the potential importance of altered
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protease activity for the pathogenesis of MFS is the observation
that treatment of mice with mutations in the Fbn1 gene with
doxycycline, a non-specific MMP inhibitor, significantly delays
aneurysm rupture in MFS-like mice by inhibiting expression of
tissue MMP-2 and MMP-9 and thus, degradation of the elastic
matrix [32,33].
The fourth LTBP domain of fibrillin-1 contains an Arg-Gly-Asp
(RDG) integrin-binding motif that mediates binding to several
integrins and thereby plays a role in adhesion and migration of
cells [34–39]. Fibrillin-1 additionally contains three Gly-x-x-Pro-
Gly (GxxPG) motifs similar to a repeated peptide in elastin, Val-
Gly-Val-Ala-Pro-Gly (VGVAPG), is known for its chemotactic
activity to fibroblasts and monocytes [40] This effect is mediated
by binding to the 67-kDa elastin binding protein (EBP) present on
the surface of mononuclear phagocytes. Elastin-derived peptides
(EDPs) released from human AAA tissue can attract mononuclear
phagocytes through ligand-receptor reactions with the EBP [41].
In previous work, we showed that fibrillin-1 fragments
containing the RGD or one of the GxxPG motifs can upregulate
MMP activity in cell culture [42,43]. This led us to investigate
whether ascending aortic samples from the fibrillin-1 under-
expressing mgR mouse model for MFS can act as chemotactic
stimuli for macrophages. Both the aortic extracts from the mgR/
mgR mice as well as a GxxPG-containing fibrillin-1 fragment
significantly increased macrophage chemotaxis compared with
extracts from wild-type mice or buffer controls. The chemotactic
response was significantly diminished by pretreatment of macro-
phages with lactose or with the elastin-derived peptide VGVAPG
and by pretreatment of samples with a monoclonal antibody
directed against an EBP recognition sequence. Additionally,
investigation of macrophages in aortic specimens of Marfan
patients demonstrated macrophage infiltration in the tunica media
[44].
The aim of the present study was to investigate whether aortic
extracts from human patients with MFS demonstrate chemotactic
stimulatory activity as previously demonstrated for the mgR mouse
model of MFS. A total of 6 patients with MFS and 8 with isolated
thoracic aortic aneurysm (TAA) were investigated.
Materials and Methods
Patient Selection and Preparation of human aortic
extracts
Fresh full-thickness aorta specimens were obtained from
patients at the time of aortic replacement or cardiac transplan-
tation at the German Heart Institute Berlin between the years
2008 and 2010. Inclusion criteria were MFS (n= 6) and isolated
TAA (n= 8). Additionally, aortic samples from eleven heart donors
with no known cardiovascular disease were obtained at the time of
heart transplantation in the operating theater during the time of
implantation of the donor heart into the recipient. The cooled
ischemic time was never longer than 3 hours, and therefore, the
aortic specimens had been on ice for maximally 3 hours at the time
the specimens were taken. The diagnosis of MFS was based on
Ghent criteria [45] (The study was completed prior to the
publication of the recently revised version of the Ghent nosology
[46]). In 5 of the Marfan patients, the diagnosis was additionally
confirmed by genetic mutation analysis.
Tissue samples (about 0.562 cm) were taken during surgery
after the initialization of cardiopulmonary bypass during cross-
clamp time and immediately following the aortotomy. Samples
were excised from the ascending aorta just above the sino-tubular
junction. Tissue samples of donor hearts were cut off during
ischemic time just before the implantation of the donor heart at
transplantation. The specimens were immediately placed into
phosphate-buffered saline (PBS) solution. Then they were stored at
4uC until they were sent to the laboratory on the same day.
Aortic tissue extracts were prepared using a modification of a
previously described protocol [41]. Briefly, the adventitia was
dissected from aorta, tissue specimens comprising the medial and
intimal layers were washed 2 times in PBS and weighed.
Specimens were then incubated in extraction buffer (PBS with 2
mol/L NaCl) overnight at 4uC with gentle shaking (20 ml per 1 g
tissue). At the end of incubation, aortic tissue was removed, and
the incubation solution was centrifuged at 10 000 rpm for 30
minutes to remove particulate debris. Aortic extract solution was
stored at 4uC for experiments on the following day (or at 20uC for
future repeats). Total protein concentration was measured by a
BCA assay kit (Pierce). Aortic specimens were divided according to
their diagnosis. Aortic extracts used for chemotaxis assay were
diluted in PBS to make a final concentration of 20 mg/ml of total
protein.
The study was approved by the ethics commission of the
Charite´ Campus Virchow-Klinikum (EA2/096/07).
Chemotaxis Assay
The murine macrophage cell line RAW 264.7 (ATCC TIB-71)
was cultured in medium containing RPMI 1640 (Biochrom AG,
Berlin, Germany), 10% FBS, and penicillin/streptomycin mix
(final concentration: penicillin, 100 IU/ml; streptomycin, 100 mg/
ml). RAW 264.7 cells have properties similar to those of mouse
resident macrophages and exhibit responsiveness to chemotactic
stimuli [47].
For harvesting the cells, monolayers of RAW 264.7 cells were
washed 2 times with PBS and then with a nonenzymatic cell
dissociation solution (Sigma-Aldrich). After 25 minutes of
incubation at room temperature, cells were suspended in PBS,
counted, centrifuged, and finally suspended in the chemotaxis
buffer consisting of RPMI 1640 supplemented with 1% bovine
serum albumin (BSA, Sigma-Aldrich) at 1|106 cells/ml.
The chemotaxis assay was performed in a 48-well chemotaxis
chamber (NeuroProbe). The bottom wells were filled with 25 ml of
attractant solution. An 8-mm-pore-diameter polyvinylpyrrolidone-
free polycarbonate filter (NeuroProbe, Gaithersburg, MD, USA)
was placed on the bottom plate. A silicon gasket and the top plate
with 48 holes were then mounted, forming the top wells. The cells
were added in a volume of 50 ml. In parallel experiments,
extraction buffer was loaded into the bottom wells as a negative
control. After 2 hours of incubation at 37uC and 5% CO2, the
filter sheet was removed, and nonmigrated cells were wiped off the
top side. The filter was then fixed in 70% methanol for 30 seconds
and stained in Wright-Giemsa (Sigma-Aldrich).
Competitive ELISA
GxxPG containing fragments concentration was measured by
using a competitive ELISA methods as described previously by
Wei et al.[48], with some modifications. Maxisorb 96-well
microtiter plates (Nunc) were coated with 50 ml of elastin peptide
(0.5 mg/ml, CB573, Elastin Products Company) in PBS, pH 7.4
and incubated overnight at 4uC. The wells were blocked with 100
ml of 0.5% BSA in PBS containing 0.05% Tween 20 (PBS-T).
Spike-and-recovery experiment detects a discrepancy between
standard diluent (PBS) and 2 fold diluted extraction buffer (Data
not shown). Therefore, in oder to generate a standard curve, a
variable concentration of elastin peptides from 10 ng/ml-10 mg/ml
diluted in 1:2 extraction buffer is mixed with a 1:1000 dilution of
the mouse monoclonal antibody derived from immunization
against bovine a-elastin (mAb BA4, Sigma-Aldrich) and incubated
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in a 0.5% BSA precoated plate. The standard curves were fitted
using a four-parameter logistic model. Simultaneously, 25 ml of
each sample was diluted 2 times with PBS and were mixed with 50
ml of 1:1000 diluted BA4 antibody. After overnight incubation
with mild shaking at 4uC, 100 ml mixtures were then added to each
well in the elastin peptide coated plate and incubated for 30 min at
37uC, the plates were washed three times with PBS-T, followed by
the addition 50 ml of secondary antibody (1:2000 anti-mouse IgG
peroxidase conjugate). After 1 hour incubation at 37uC, the plates
were washed three times, 50 ml of tetramethylbenzidine substrate
solution (Thermo Fisher Scientific, San Jose, CA) was added, and
after 10 minutes incubation at room temperature the reaction was
quenched by adding 50 ml 1 M H2SO4 to each well. The
absorbance was measured at 450 nm using a micro-plate reader.
The accuracy and precision of the quantitative range of the ELISA
was determined by replicate analyses. The concentration of
GxxPG containing fragments was normalized against the total
protein concentration of the aortic extracts.
Experimental Design
Aortic extracts from patients with MFS and isolated TAA were
compared against control aortic extracts derived from heart
donors with no known cardiovascular disease. Our previous work
on the chemotactic stimulatory potential of aortic extracts from the
mgR Marfan mouse model had suggested that the chemotactic
activity of aortic extracts is at least partially mediated by EBP [44].
Therefore, we performed several experiments to investigate
whether the chemotactic activity of human aortic samples is also
mediated by the EBP.
BA4 can block the chemotactic activity of VGVAPG, a
repeated amino acid sequence motif in elastin that is know to
bind to the EBP [41]. Preincubation of monocytes with VGVAPG
peptides can also block the chemotactic response [40]. The EBP is
known to dissociate in the presence of high levels of lactose, but
not glucose [49]. Therefore, to investigate a potential role with
EBP in the chemotaxis experiments described in this manuscript,
cells were exposed to 1 mmol/L lactose or glucose, or 0.1 mmol/L
VGVAPG for 1 hour incubation at 37uC before the chemotaxis
assays were started. As a further control, samples were
preincubated for 30 minutes at room temperature with BA4 or
with murine IgG (Sigma-Aldrich), both at a dilution of 1:1000. All
assays were done in triplicate during the same experiment. In each
well, 4 random fields were chosen with the microscope set at x200
magnification. The fields were observed and recorded photo-
graphically with the Leica DC viewer program. Fields were scored
by 2 observers blinded to the chemotactic stimulus (or control)
using an in-house Java program. PBS was loaded into the bottom
wells as a negative control. The results were expressed as the
chemotactic index (CI) that is the number of cells having migrated
in the presence of the chemotactic agent divided by the number of
cells having migrated in the presence of extraction buffer alone.
Statistical analysis
Data shown represent the mean+SD (standard deviation). The
value for the mean BA4 reactivity and chemotactic index (CI) of
each group was compared using the Student’s t test. Additionally,
Fisher’s exact test was performed to compare the gender
distribution in the two patients groups, and the Mann-Whitney
test was performed to compare age, CI and BA4 reactivity
between two patient groups. Statistical significance was accepted
at Pv0.05.
Results
The mgR mouse underexpresses fibrillin-1 and recapitulates
many of the clinical features of human MFS [50]. In previous
Table 1. Characteristics of the patients included in this study.
Patient Diagnosis Age Sex Description
1 MFS 23 m Dilatation and dissection of the ascending aorta and abdominal aorta, maximum diameter of ascending aorta 4 cm.
Atenolol.
2 MFS 45 m Aneurysm of ascending and descending aorta, status post previous surgical repair of ascending aorta with leakage
of anastomosis.
3 MFS 21 f Sinus valsalvae aortic aneurysm, status post previous surgical repair of ascending aorta. Metoprolol.
4 MFS 65 m Infrarenal aortic aneurysm, maximum diameter 6.1 cm. Status post previous surgical repair of ascending aorta.
Nebivolol.
5 MFS 37 m Thoraco-abdominal aneurysm, status post previous surgical repair of ascending aorta. Nebivolol.
6 MFS 40 m Dilatation of ascending aorta
7 TAA 62 m Aneurysm of ascending aorta, III0 aortic insufficiency. Metastatic colon cancer
8 TAA 40 m Subacute dissection of the ascending aorta, status post previous surgical repair of ascending aorta, Erdheim-Gsell
media degeneration, maximal diameter of sinus valsavae 4.1 cm. FBN1 mutation excluded.
9 TAA 65 m Aneurysm of ascending aorta, maximal diameter 6.3 cm, three-vessel coronary artery disease, arterial hypertension,
hyperlipoproteinemia, sleep apnea syndrome.
10 TAA 71 m Acute type A dissection, maximal diameter 4.2 cm. Arterial hypertension, hyperlipoproteinemia
11 TAA 73 m Aneurysms of ascending and abdominal aorta. Maximal diameter of ascending aorta 5.3 cm. Arterial hypertension,
hyperlipoproteinemia, osteoporosis
12 TAA 60 m Dilatation of the ascending aorta, status post surgical replacement of the aortic valve. III0 atrioventricular block
13 TAA 43 m Type A dissection, septic multiorgan failure related to fulminant pneumonia, status post surgical supracoronary
aorta replacement.
14 TAA 55 m Aneurysm of the ascending aorta. Combined vitium of the aortic valve. Arterial hypertension.
MFS: Marfan syndrome; TAA: isolated thoracic aortic aneurysm; m: male, f: female; The column Description provides details of the indications for aortic surgery and
information about other relevant medical conditions, and treatment with beta blockers.
doi:10.1371/journal.pone.0020138.t001
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work, we showed that aortic extracts of the mgR mouse induce
macrophage chemotaxis. The chemotactic inductive effect could
be inhibited by pretreating the macrophages with lactose, which
causes shedding of the elastin-binding protein, or by pretreatment
of the aortic extracts with the monoclonal antibody BA4, which
reacts against bioreactive GxxPG motifs in elastin [51] and, as we
showed, against a GxxPG motif in fibrillin-1 [44]. In this work, we
asked whether aortic extracts from human Marfan patients would
similarly induce macrophage chemotaxis and whether evidence
could be obtained that this effect is at least partially mediated by
EBP.
Clinical data
Six specimens were obtained from individuals with MFS and
eight specimens were obtained from individuals with isolated
TAA. Four of the Marfan patients were receiving prophylactic
treatment with beta blockers at the time of the operation.
Additionally, samples from 11 heart donors with no known
cardiovascular disease were used as controls. The average age of
the patients with MFS was 38.5+16.1 years, and five of the six
patients were male. The average age of the patients with isolated
TAA was 58.6+12.1 years, and all eight patients were male.
Details of patient characteristics are shown in Table 1. There is a
significant difference regarding age between MFS and TAA group
(Table 2).
Analytical performance of ELISA
BA4 reactivity was determined from calibration curve derived
from standards of known elastin peptide concentration (from 10
ng/ml to 10 mg/ml). The quantitative range of the assay was 75
ng/ml to 2 mg/ml (80–20% inhibition values), with 50% inhibitory
concentration at 390 ng/ml. The precision of the assay was
acceptable with intra- and inter-assay coefficients of variation (CV)
ranged from 2.5% to 6.3% and 2.6% to 8.7%, respectively. These
results indicated that the values obtained with competitive ELISA
in this study were highly reproducible and reliable.
Higher BA4 reactivity in aortic extracts from Marfan
patients
We first asked whether the concentration of GxxPG fragments
(defined operationally as reactivity against the BA4 antibody) was
increased in specimens from individuals with MFS. As described in
methods, we developed an ELISA assay based on the BA4
antibody to measure GxxPG containing fragments. The BA4
reactivity was significantly higher in Marfan patients (Pv0:05)
and also in patients with isolated TAA (Pv0:05) compared with
control specimens (Figure 1A).
Aortic extracts from Marfan patients demonstrate
chemotactic activity
We then used aortic extracts from the same samples to
investigate a potential induction of macrophage chemotaxis.
Extracts from Marfan patients showed significantly higher
chemotactic activity (CI = 2.58+0.42, Pv0:01) than that of 11
Table 2. Comparison between the two patient groups.
MFS TAA P-value
Male 5 8 .429
Age(years) 39+16 59+12 .020
CI 2.58+0.42 2.45+1.42 .804
BA4 reactivity
(mg/mg)
7.495+1.93 8.409+6.884 .670
The third column shows the P-value calculated with the Fisher’s exact test for
categorical data and by the Mann-Whitney test for quantitative data.
doi:10.1371/journal.pone.0020138.t002
Figure 1. BA4 reactivity and chemotactic activity of human aortic extracts. (A) BA4 reactivity was measured by competitive ELISA in aortic
extracts from patients with MFS (n = 6), isolated TAA (n= 8) and controls (n = 11). A statistically significant increase in BA4 reactivity as compared to
control samples was observed for the samples from individuals with MFS and isolated TAA. (B) Chemotactic activity of the same extracts was
measured by a Boyden chamber. A statistically significant increase in chemotactic activity as compared to control samples was observed for the
samples from individuals with MFS and isolated TAA. Red lines indicate the median levels of BA4 reactivity or chemotactic index (CI). Data are
representative of three independent experiments. * Pv0.05, **Pv0.01.
doi:10.1371/journal.pone.0020138.g001
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control samples (CI= 1.42+0.61) (Figure 1B). The maximal RAW
264.7 migration upon stimulation by aortic extracts from
individuals with MFS was 110% of that observed upon stimulation
with 10{7 mmol/L VGVAPG. The CI of RAW 264.7 cells
toward extracts from patients with isolated TAA was significantly
higher (CI = 2.45+1.22, Pv0:05) compared with control samples
(Figure 1B), and maximal RAW 264.7 migration upon stimulation
by extracts from TAA group was around 135% of that with 10{7
mmol/L VGVAPG. There was a statistically significant positive
correlation (r~0:6,Pv0:01) between BA4 reactivity and CI
(Figure 2).
To investigate whether chemotactic inductive activity of aortic
extracts from patients with MFS is related to EBP, chemotaxis
analysis was performed as described in methods. As the results
shown chemotactic response of aortic extracts reduced significant-
ly after lactose and VGVAPG pretreatment, whereas no effects
were observed in cells exposed to glucose (Figure 3). Additionally,
preincubation of aortic extracts with BA4 resulted in a significant
reduction of the CI of RAW 264.7 in both groups (Figure 3).
These results indicate that the chemoattractive ability of extracts
from patients with MFS is at least partially dependent on EBP.
Discussion
The results of this study show that extracts from the ascending
aorta from patients with MFS possess increased reactivity for the
monoclonal antibody BA4, which reacts with an epitope that has
been mapped to VGVAPG in elastin [43,52]. The samples
additionally showed a statistically significant ability to induce
macrophage chemotaxis in a Boyden chamber assay (Figure 1).
Because of the fact that the chemotaxis inductive effect could be
inhibited by pretreatment of the cells with lactose or pretreatment
of the samples with BA4, we infer that the induction of chemotaxis
is at least partially due to increased concentrations of elastin and
perhaps fibrillin degradation products containing an GxxPG
epitope. This interpretation is further supported by the statistically
significant correlation between the BA4 reactivity and CI of aortic
samples (Figure 2).
Elastin is the dominant ECM protein in the tunica media of the
arterial and aortic wall, which is composed of a dense population
of concentrically organized vascular smooth muscle cells (vSMCs)
that synthesize elastin molecules and secrete them as soluble,
hydrophobic monomers termed tropoelastin. As a part of the
aging process, the aortic wall undergoes a number of alterations
including fibrosis and elastin fragmentation, characterized by
disruption of elastin lamellae [53]. Correspondingly, the concen-
tration of soluble elastin fragments in serum gradually increases in
healthy subjects with aging [54]. Elastin fragmentation is known to
be a component of the complex pathogenesis of pulmonary
emphysema, which results in part from elastic tissue digestion by
unrestrained elastase activity in the lung in turn leading to the
release of soluble elastin fragments (EDP), which may be measured
in plasma by an ELISA [55]. Elastin has multiple cell hydrophobic
repeating sequences with a core sequence of GxxPG that can
induce a chemotactic response [56], and EDPs have been shown
to drive disease progression in a mouse model of emphysema [57].
There is some suggestive evidence that EDPs may contribute to
progression of vascular diseases. Soluble EDPs released within
human abdominal aortic aneurysm tissue can attract mononuclear
phagocytes by interacting with the 67-kD EBP [57], this
observation offers a plausible, if unproven explanation for the
inflammatory response that often accompanies abdominal aneu-
rysmal degeneration. EDPs can induce free radical and protease
production and induce oxidation of low density lipoproteins by
Figure 2. BA4 reactivity (mg/mg) versus chemotactic index (CI)
of human aortic extracts, with calculated Pearson correlation
coefficient (r) and P value.
doi:10.1371/journal.pone.0020138.g002
Figure 3. Chemotactic index (CI) of RAW 264.7 cells upon
stimulation with aortic extracts from individuals with MFS
(n~6). (A) RAW 264.7 cells were preincubated with 1 mmol/L lactose
or glucose for one hour at 37uC prior to exposure to aortic extracts.
There was a statistically significant inhibition of chemotaxis. (B) RAW
264.7 cells were preincubated with 0.1 mmol/L VGVAPG hexapeptide
for 1 hour incubation at 37uC before the chemotaxis assays were
started. There was a statistically significant inhibition of the chemotactic
response after VGVAPG pretreatment. (C) Aortic extracts were
preincubated with BA4 or non-specific IgG for 30 minutes at room
temperature prior to chemotaxis assays. There was a statistically
significant inhibition of the chemotactic response by BA4 pretreatment.
Data are representative of three independent experiments. * Pv0.05,
**Pv0.01.
doi:10.1371/journal.pone.0020138.g003
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phagocytic cells [58,59]. However, the relation of elastin and
human arterial disease is complex and incompletely understood.
Macrophages are not only able to be attracted by elastin
fragments, but can themselves produce the elastin precursor
elastin, and may contribute to the increase in tropoelastin content
that is characteristic of human abdominal aortic aneurysms and
atheromas [60].
In the present study, we have presented evidence that aortic
extracts from patients with MFS contain increased concentrations
of EDPs that react with BA4 and are able to induce macrophage
chemotaxis. We had previously shown that aortic extracts of a
mouse model of MFS as well as a GxxPG-carrying fibrillin-1
fragment can induce macrophage chemotaxis by a mechanism
that is at least partially mediated by the 67-kD EBP [44]. The
results of the current study have shown a similar phenomenon for
aortic specimens from human Marfan patients. Together with the
finding of a modest but statistically significant increase in the
number of CD68z macrophages in aortic specimens of Marfan
patients [44], our findings provide suggestive evidence that
secondary effects of elastin fragments including the induction of
macrophage chemotaxis may contribute to the complex patho-
genesis of MFS. Further studies will be required to determine
whether elastin fragments drive disease progression or whether
they represent an epiphenomenon.
Eight patients underwent prophylactic aortic operations because
of isolated (idiopathic) TAA. Several genes and genetic loci have
been identified for familial TAA [61], although the etiology of
most cases of isolated TAA still remains unknown. Genetic testing
was not performed on the eight patients with TAA, but there were
no clinical signs suggestive of known monogenic forms of TAA
such as Loeys-Dietz syndrome. Given the average age of
58.6+12.1 years in this group of patients, and the history of
arterial hypertension in several patients, it appears likely that most
if not all of these patients do not have a monogenic form of TAA.
BA4 reactivity and the chemotactic index for the TAA group was
statistically significantly increased, although the individual values
showed a larger dispersal than did the samples from the Marfan
patients.
In summary, this work has shown that aortic extracts from
individuals with MFS and isolated TAA can induce macrophage
chemotaxis modulated by the 67-kD EBP. This suggests that
elastin fragmentation may be a common response of the damaged
aorta. A limitation of our study is related to the fact that no
identifying data are available for the control aortic specimens,
which were obtained from deceased heart donors with no known
cardiovascular disease. Therefore, confounding effects related to
age or gender cannot be excluded. It remains to be determined
whether secondary effects of these fragments that are modulated
by the 67-kD EBP drive progression of some or all of these
diseases. Since increased GxxPG epitope was observed in aortic
extracts from both Marfan and TAA patients, it will be interesting
to develop a more sensitive ELISA method to investigate the level
of GxxPG in serum of individuals affected by MFS or other aortic
aneurysm related disease.
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